The Department of Justice, through its Antitrust Division, has brought a significant civil antitrust action against medical device giants Edwards LifeSciences Corp. and Genesis MedTech Group Limited. Filed on July 13, 2026, in the United States District Court for the District of Columbia, the complaint alleges that the companies deliberately structured Edwards' 2024 acquisition of JC Medical, Inc. to bypass the pre-merger notification and waiting requirements of the Hart-Scott-Rodino (HSR) Antitrust Improvements Act. This legal challenge underscores the federal government's commitment to enforcing merger control laws and preventing anticompetitive practices.
Understanding the Hart-Scott-Rodino Act
The HSR Act is a cornerstone of modern antitrust enforcement, designed to give federal antitrust agencies, namely the Federal Trade Commission and the Department of Justice, an opportunity to review significant mergers and acquisitions before they are completed. This pre-merger scrutiny is crucial for identifying and challenging potentially anticompetitive transactions that could harm consumers through reduced competition, higher prices, or diminished innovation. The Act requires parties to transactions exceeding certain annually adjusted dollar-value thresholds to notify the agencies and observe a waiting period. At the time of the JC Medical acquisition, the threshold was $119.5 million.
A critical component of HSR enforcement is Rule 801.90, which explicitly states that any transaction or device employed to avoid HSR compliance will be disregarded, and the obligation to comply will be determined by the substance of the transaction, not its form. This anti-avoidance rule is central to the DOJ's case against Edwards and Genesis, highlighting the intent and structure of the deal as paramount to its legality under HSR.
The Alleged HSR Avoidance Scheme
The DOJ's complaint details how Edwards, a Delaware corporation, acquired JC Medical from Singapore-based Genesis. On July 22, 2024, Edwards paid $115 million for JC Medical, a sum intentionally kept just below the $119.5 million HSR threshold. However, concurrently with this acquisition, Edwards also committed to a $25 million investment in Genesis itself. The DOJ alleges that if these payments were aggregated, the true value of the transaction would have easily surpassed the HSR reporting threshold, triggering notification requirements.
Evidence cited in the complaint, including internal documents and testimony, suggests that Edwards and Genesis were aware of and intended to exploit this structural separation to avoid HSR review. Edwards was reportedly concerned that HSR review would delay the closing of the JC Medical acquisition, particularly as it was simultaneously negotiating to acquire JenaValve Technology, Inc. This concurrent negotiation is critical, as JC Medical and JenaValve were, at the time, the only two companies in the United States conducting clinical trials for transcatheter aortic valve replacement for aortic regurgitation, or TAVR-AR devices. Genesis, on its part, valued JC Medical at $125-150 million and was initially unwilling to accept an offer below the HSR filing threshold, leading to the proposed two-part payment structure.
The alleged scheme allowed Edwards to close the JC Medical acquisition without HSR filing or a public announcement. The day after, Edwards moved to acquire JenaValve, aiming to consolidate control over the entire nascent TAVR-AR market in the United States.
Broader Antitrust Concerns and Implications
Beyond the HSR Act violation, the DOJ's complaint implicitly points to broader antitrust concerns. Edwards' alleged strategy to acquire both JC Medical and JenaValve, the only two clinical-stage competitors in the promising TAVR-AR device market, suggests a potential intent to create a monopoly. Such actions could stifle innovation, limit patient choice, and ultimately lead to higher costs for a critical medical treatment.
The federal antitrust agencies rely on the HSR Act's notification requirements to identify and intervene in such market-altering transactions before they are consummated and cause irreversible harm. When companies deliberately circumvent these requirements, it not only undermines the legal framework but also risks allowing anticompetitive mergers to proceed unchallenged, harming the public interest.
The Proposed Resolution and Future Precedent
The proposed Final Judgment, filed alongside the complaint, seeks to remedy these violations. It requires Edwards LifeSciences to pay a civil penalty of $10 million and Genesis MedTech Group Limited to pay $2 million. Furthermore, Edwards must institute an antitrust compliance program to ensure future adherence to antitrust laws. Critically, Edwards is now also mandated to provide notice to the Federal Trade Commission prior to acquiring any part of a firm selling or conducting clinical trials in the United States for a TAVR-AR device. This forward-looking requirement aims to prevent similar circumventions and ensure transparency in a crucial medical technology market.
This action serves as a strong reminder that the DOJ and FTC are vigilant against attempts to bypass HSR requirements, especially when such maneuvers appear designed to facilitate market consolidation that could raise competitive concerns. The public has 60 days from July 23, 2026, to submit comments on the proposed Final Judgment, a standard procedure allowing stakeholders to provide input on antitrust settlements.
